Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Depreciation & Amortization (CF): 2021-2025

Historic Depreciation & Amortization (CF) for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $391,000.

  • ARS Pharmaceuticals' Depreciation & Amortization (CF) rose 291.00% to $391,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 609.22%. This contributed to the annual value of $100,000 for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Depreciation & Amortization (CF) of $391,000 as of Q3 2025, which was up 40.14% from $279,000 recorded in Q2 2025.
  • ARS Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $391,000 during Q3 2025, with a 5-year trough of -$37,000 in Q2 2022.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $50,000 (2024), whereas its average is $116,455.
  • Per our database at Business Quant, ARS Pharmaceuticals' Depreciation & Amortization (CF) tumbled by 117.70% in 2022 and then surged by 2,445.45% in 2025.
  • ARS Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $204,000 in 2021, then slumped by 93.14% to $14,000 in 2022, then dropped by 14.29% to $12,000 in 2023, then skyrocketed by 316.67% to $50,000 in 2024, then skyrocketed by 291.00% to $391,000 in 2025.
  • Its Depreciation & Amortization (CF) was $391,000 in Q3 2025, compared to $279,000 in Q2 2025 and $280,000 in Q1 2025.